Open-label Safety and Tolerability Study of LTS-PDT in Healthy Volunteers



Status:Completed
Conditions:Acne, Acne, Dermatology
Therapuetic Areas:Dermatology / Plastic Surgery
Healthy:No
Age Range:18 - Any
Updated:7/16/2013
Start Date:April 2013
End Date:June 2013
Contact:Irina Krause
Email:ikrause@tklresearch.com
Phone:(201) 587-0500

Use our guide to learn which trials are right for you!

An Open-label Safety and Tolerability Study of LTS 0.3% With Ref Light Applied to the Backs of Healthy Volunteers


The purpose of this study is assess the safety and tolerability of lemuteporfin topical
solution (LTS) with exposure to red light (PDT), when applied to the backs of healthy
volunteers.


This is an open-label, safety study in healthy volunteers. Two cohorts, of 6 subjects each,
will be enrolled (total subjects = 12). Each subject will have test areas identified on the
back and receive a single LTS, vehicle solution and red light (PDT) applied to the test
areas on the back. Subjects will be followed for safety at study visits occurring on Day 1
(baseline and treatment), Day 2, and Day 7.

Inclusion Criteria:

1. Healthy adults 18 years of age or older

2. Fitzpatrick skin types I-IV

Exclusion Criteria:

1. Current pregnancy or lactation.

2. Presence of severe facial acne, acne fulminans or conglobata, or nodulocystic acne.

3. Poor skin condition on the back, including erythema, dryness, sunburn, dermatological
malignancies, infections, cuts, abrasions, tattoo, excess of hair or any other skin
condition

4. Subjects who have used any agents known to produce significant photosensitivity
reactions (tetracyclines, phenothiazines, trimethoprim, etc.) within 2 weeks of Day 1
or 5 half-lives, whichever is longer.

5. Subjects who have used any medicated topical therapy on the back within 3 days of Day
1.

6. Chronic treatment with low dose aspirin, a non-steroidal anti inflammatory drug
(NSAID), or an anticoagulant regimen such as warfarin (Coumadin).

7. Abnormal findings on screening ECG deemed clinically significant by the Investigator.

8. Active participation in an experimental therapy study or experimental therapy within
30 days of Day 1.

9. Screening clinical chemistry or hematology laboratory value that is considered
clinically significant, in the opinion of the Investigator.

10. Subjects who are a poor medical risk because of other systemic diseases or active
uncontrolled infections.
We found this trial at
1
site
?
mi
from
Paramus, NJ
Click here to add this to my saved trials